Allos Allos Pharma Inc. Receives FDA Guidance for the Design of a Phase 3 Trial to Support a New Drug Application for Treatment of Fragile X Syndrome
Allos Allos Pharma Inc. presents new positive data analyses at the 18th NFXF International Fragile X Conference
